Abstract: Systems and methods are disclosed for managing logistics information related to a container using a container interface display apparatus. A scanner on the container interface display apparatus identifies an item during loading of the container. An association between the container and the item is recorded in memory of the container interface display apparatus as part of managed logistics information related to the container. A scale within the container detects a weight of the item and sends a signal to the container interface display apparatus indicating the detected weight of the item (which is also recorded in memory as part of the managed logistics information related to the container). Electronic logistics monitor information (e.g., at least a portion of the managed logistics information) is then generated on the display screen of the container interface display apparatus.

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.

Abstract: Methods, apparatus, and systems are described for generating a content related notification based upon managed logistics information related to a container using a container interface display apparatus. Such a container interface display apparatus records an update to the managed logistics information maintained in a memory of the container interface display apparatus and then accesses at least a portion of the managed logistics information maintained in the memory after recording the update. The container interface display apparatus then detects a notification event based upon the accessed portion of the managed logistics information. Such notification event is related to status information associated with the container or an item stored within the container.

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: Methods, apparatus, and systems are described for managing logistics information related to a container using a container interface display apparatus. The container interface display apparatus may comprise a mountable housing, a display screen, a memory, a scanner, and a wireless communication interface. The housing is coupled to the container to permit the scanner to identify an item being loaded for shipment within the container. The scanner identifies the item, and the apparatus records an association in memory as part of managed logistics information that reflects an established and tracked relationship between the container and the item. The apparatus increments package count information (another part of the managed logistics information) to reflect that the item is loaded within the container. The apparatus generates electronic logistics monitor information on the display screen to include at least a portion of the managed logistics information related to the container.

Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Abstract: The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.

Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.

Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Abstract: The present invention provides solid forms of compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, methods of producing the same, and methods of using the same in the treatment of ACC-mediated diseases.

Abstract: The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Abstract: A device and associated method for lifting leaves from a pile in larger quantities that is traditionally possible using a shovel or rake is described. Broadly, the device comprises a plastic or fabric flexible rectangular sheet having at least a pair of parallel elongated rods affixed to opposing sides of the sheet. At least some embodiments further include an elongated handle, often in the form of a rod, connected with and extending outwardly from one of the elongated rods.

Abstract: The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment o RORgammaT-mediated diseases or conditions.